NASDAQ
IVA

Inventiva Sa

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Inventiva Sa Stock Price

Vitals

Today's Low:
$3.46
Today's High:
$3.69
Open Price:
$3.46
52W Low:
$2.22
52W High:
$7.47
Prev. Close:
$3.72
Volume:
3765

Company Statistics

Market Cap.:
$160.89 million
Book Value:
1.08
Revenue TTM:
$18.81 million
Operating Margin TTM:
-303.81%
Gross Profit TTM:
$18.81 million
Profit Margin:
-288.48%
Return on Assets TTM:
-30.02%
Return on Equity TTM:
-80.8%

Company Profile

Inventiva Sa had its IPO on 2020-07-10 under the ticker symbol IVA.

The company operates in the Healthcare sector and Biotechnology industry. Inventiva Sa has a staff strength of 109 employees.

Stock update

Shares of Inventiva Sa opened at $3.46 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.46 - $3.69, and closed at $3.69.

This is a -0.81% slip from the previous day's closing price.

A total volume of 3,765 shares were traded at the close of the day’s session.

In the last one week, shares of Inventiva Sa have increased by +0.82%.

Inventiva Sa's Key Ratios

Inventiva Sa has a market cap of $160.89 million, indicating a price to book ratio of 2.299 and a price to sales ratio of 19.1815.

In the last 12-months Inventiva Sa’s revenue was $18.81 million with a gross profit of $18.81 million and an EBITDA of $-56314000. The EBITDA ratio measures Inventiva Sa's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Inventiva Sa’s operating margin was -303.81% while its return on assets stood at -30.02% with a return of equity of -80.8%.

In Q4, Inventiva Sa’s quarterly earnings growth was a positive 0% while revenue growth was a positive 142.8%.

Inventiva Sa’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.43 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Inventiva Sa’s profitability.

Inventiva Sa stock is trading at a EV to sales ratio of 27.4337 and a EV to EBITDA ratio of -2.04. Its price to sales ratio in the trailing 12-months stood at 19.1815.

Inventiva Sa stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$116.00 million
Total Liabilities
$30.70 million
Operating Cash Flow
$0
Capital Expenditure
$158000
Dividend Payout Ratio
0%

Inventiva Sa ended 2024 with $116.00 million in total assets and $0 in total liabilities. Its intangible assets were valued at $116.00 million while shareholder equity stood at $45.48 million.

Inventiva Sa ended 2024 with $0 in deferred long-term liabilities, $30.70 million in other current liabilities, 421000.00 in common stock, $-54274000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $86.74 million and cash and short-term investments were $87.79 million. The company’s total short-term debt was $5,851,000 while long-term debt stood at $28.66 million.

Inventiva Sa’s total current assets stands at $106.38 million while long-term investments were $700000.00 and short-term investments were $1.05 million. Its net receivables were $9.34 million compared to accounts payable of $19.36 million and inventory worth $373000.00.

In 2024, Inventiva Sa's operating cash flow was $0 while its capital expenditure stood at $158000.

Comparatively, Inventiva Sa paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$3.69
52-Week High
$7.47
52-Week Low
$2.22
Analyst Target Price
$

Inventiva Sa stock is currently trading at $3.69 per share. It touched a 52-week high of $7.47 and a 52-week low of $7.47. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $3.83 and 200-day moving average was $4.18 The short ratio stood at 4.08 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 1218.1% are held by institutions.

Frequently Asked Questions About Inventiva Sa

The stock symbol (also called stock or share ticker) of Inventiva Sa is IVA

The IPO of Inventiva Sa took place on 2020-07-10

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Hemo Organic Limited (HEMORGANIC)
$6.85
0.32
+4.9%
$90.48
0.88
+0.98%
$81.32
0.7
+0.87%
$0.31
0.01
+4.1%
$2.43
0
0%
$31.41
0.09
+0.29%
$2.84
0.05
+1.79%
$164.09
2.54
+1.57%
$43.8
-2.3
-4.99%
Aon PLC (AON)
$334.99
1.84
+0.55%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Address

50 rue de Dijon, Daix, France, 21121